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Signaling through the Akt/mammalian target of rapamycin
(mTOR) pathway plays a pivotal role in the regulation of
multiple cellular processes, including proliferation, apopto-
sis, protein synthesis and autophagy. It is therefore a major
target of microbial infections and tumors. Protozoa of the
Leishmania genus cause a wide spectrum of diseases in
humans, termed leishmaniases, with clinical manifestations
ranging from self-healing skin ulcers to life-threatening
visceral disease. These parasites primarily infect macro-
phages and are renowned for their ability to sabotage
host-cell signal transduction pathways. Here, we report
that infection of Balb/c bone marrow-derived macro-
phages with the promastigote stage of Leishmania major
results in rapid, time-dependent degradation of key com-
ponents of the Akt/mTOR axis, including Akt, mTOR
and the tuberous sclerosis complex-2 (TSC-2). Disrup-
tion of the Akt/mTOR pathway by L. major is dependent
on the surface metalloprotease gp63, an important viru-
lence factor of the parasite, and appears to be strain- and
species-specific. The consequences of the degradation of
key intermediates in the Akt/mTOR pathway on down-
stream responses are currently being investigated. These
studies highlight a novel mechanism by which L. major
interferes with macrophage functions and responses and
will provide a better understanding of Leishmania
pathogenesis.
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